All In Biotech

Drug Trial Radar · NCT01578499

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)

A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 131 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

131

Actual

Start

Jun 11, 2012

Primary completion

May 31, 2016

Study completion Jul 6, 2018

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
Collaborators
Seagen Inc.
First posted
Apr 17, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine objective response rate (ORR), lasting at least 4 months (ORR4), with brentuximab vedotin in participants with cluster of differentiation antigen 30 positive (CD30+) cutaneous T-cell lymphoma \[mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL) \]compared to that achieved with therapy in the control arm.

Conditions

  • Primary Cutaneous Anaplastic Large Cell Lymphoma
  • Mycosis Fungoides
  • Cutaneous T-Cell Lymphoma

Interventions

  • Brentuximab VedotinDrug

    Brentuximab vedotin intravenous injection.

  • MethotrexateDrug

    Methotrexate tablets.

  • BexaroteneDrug

    Bexarotene tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4)Time frame: Each Cycle until disease progression, death End of treatment (Median overall follow-up 38.8 months)

Locations

41 sites in 12 countries. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

  • Site not named

    Palo Alto, California

  • Site not named

    Chicago, Illinois

  • Site not named

    Boston, Massachusetts

  • Site not named

    Hackensack, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Houston, Texas

  • Site not named

    East Melbourne, Australia

  • Site not named

    Concord, New South Wales, Australia

  • Site not named

    South Brisbane, Queensland, Australia

  • Site not named

    Adelaide, South Australia, Australia

  • Site not named

    Nedlands, Western Australia, Australia

  • Site not named

    Sankt Pölten, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Leuven, Belgium

  • Site not named

    São Paulo, Brazil

  • Site not named

    Nantes, France

  • Site not named

    Paris, France

  • Site not named

    Pessac, France

  • Site not named

    Pierre-Bénite, France

  • Site not named

    Reims, France

  • Site not named

    Kiel, Germany

  • Site not named

    Krefeld, Germany

  • Site not named

    Mainz, Germany

  • Site not named

    Mannheim, Germany

  • Site not named

    Minden, Germany

  • Site not named

    Würzburg, Germany

  • Site not named

    Bologna, Italy

  • Site not named

    Florence, Italy

  • Site not named

    Meldola, Italy

  • Site not named

    Warsaw, Poland

  • Site not named

    Barcelona, Spain

  • Site not named

    Madrid, Spain

  • Site not named

    Pamplona, Navarre, Spain

  • Site not named

    Zurich, Switzerland

  • Site not named

    Birmingham, United Kingdom

  • Site not named

    Glasgow, United Kingdom

  • Site not named

    London, United Kingdom

  • Site not named

    Manchester, United Kingdom

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.